{
    "xml": "<topic id=\"PHP3354\" outputclass=\"drug\" rev=\"1.25\" type=\"drug\" namespace=\"/drugs/ticarcillin-with-clavulanic-acid\" basename=\"ticarcillin-with-clavulanic-acid\" title=\"TICARCILLIN WITH CLAVULANIC ACID\">\n<title>TICARCILLIN WITH CLAVULANIC ACID</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_180\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/penicillins/ticarcillin\">Ticarcillin</xref>\n</p>\n<data name=\"vtmid\">346687005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_992468136\" title=\"Penicillins (antipseudomonal)\">Penicillins (antipseudomonal)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34546\" title=\"PENICILLINS\" namespace=\"/drug-classes/penicillins\">PENICILLINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP40363\" outputclass=\"indicationsAndDose\" rev=\"1.58\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Infections due to <ph outputclass=\"organism\">\n<i>\n<i>Pseudomonas</i>\n</i>\n</ph> and <ph outputclass=\"organism\">\n<i>\n<i>Proteus</i>\n</i>\n</ph> spp</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3.2&#8239;g every 6&#8211;8&#8239;hours; increased if necessary to 3.2&#8239;g every 4&#8239;hours, increased frequency used for more severe infections.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41001\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">High doses may lead to hypernatraemia (owing to sodium content of preparations)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Cholestatic jaundice</p>\n<p>Cholestatic jaundice is possibly associated with clavulanic acid. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav (amoxicillin, clavulanic acid) than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39524\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Eosinophilia</ph>; <ph outputclass=\"sideEffect\">haemorrhagic cystitis (more frequent in children)</ph>; <ph outputclass=\"sideEffect\">hypokalaemia</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40121\" outputclass=\"pregnancy\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41098\" outputclass=\"breastFeeding\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Trace amounts in milk, but appropriate to use.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40500\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39810\" outputclass=\"renalImpairment\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose to 3.2&#8239;g every eight hours if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 1.6&#8239;g every eight hours if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 1.6&#8239;g every twelve hours if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Accumulation of electrolytes contained in preparation can occur in patients with renal failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38517\" outputclass=\"effectOnLaboratoryTests\" rev=\"1.8\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Effect on laboratory tests</title>\n<body>\n<section>\n<sectiondiv>\n<p>False-positive urinary glucose (if tested for reducing substances).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41219\" outputclass=\"directionsForAdministration\" rev=\"1.17\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Timentin</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Glucose 5%. Suggested volume (depending on dose) 100&#8211;150&#8239;mL; give over 30&#8211;40 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58030\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dose is expressed as a combination of ticarcillin (as sodium salt) and clavulanic acid (as potassium salt) in a ratio of 15:1.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3354-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ticarcillin-with-clavulanic-acid\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76285\" title=\"Powder for solution for infusion\" namespace=\"/drugs/ticarcillin-with-clavulanic-acid/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78491\" namespace=\"/treatment-summaries/blood-infections-bacterial\" title=\"Blood infections, bacterial\" count=\"2\" rel=\"backlink\">Blood infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78502\" namespace=\"/treatment-summaries/penicillins\" title=\"Penicillins\" count=\"1\" rel=\"backlink\">Penicillins</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_180\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/penicillins/ticarcillin\" title=\"Ticarcillin\" count=\"1\" rel=\"link\">Ticarcillin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34546\" namespace=\"/drug-classes/penicillins\" title=\"PENICILLINS\" count=\"1\" rel=\"link\">PENICILLINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76285\" namespace=\"/drugs/ticarcillin-with-clavulanic-acid/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP3354",
    "outputclass": "drug",
    "rev": "1.25",
    "type": "drug",
    "namespace": "/drugs/ticarcillin-with-clavulanic-acid",
    "basename": "ticarcillin-with-clavulanic-acid",
    "title": "TICARCILLIN WITH CLAVULANIC ACID",
    "interactants": [
        {
            "id": "bnf_int_180",
            "label": "Ticarcillin"
        }
    ],
    "vtmid": "346687005",
    "drugClassification": [
        "Penicillins (antipseudomonal)"
    ],
    "inheritsFromClass": [
        "PENICILLINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Infections due to Pseudomonas and Proteus spp",
                        "html": "Infections due to <ph outputclass=\"organism\"> <i> <i>Pseudomonas</i> </i> </ph> and <ph outputclass=\"organism\"> <i> <i>Proteus</i> </i> </ph> spp",
                        "organism": "Proteus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion",
                    "organism": "Proteus"
                },
                "adult": [
                    {
                        "textContent": "3.2 g every 6&#8211;8 hours; increased if necessary to 3.2 g every 4 hours, increased frequency used for more severe infections.",
                        "html": "<p>3.2&#8239;g every 6&#8211;8&#8239;hours; increased if necessary to 3.2&#8239;g every 4&#8239;hours, increased frequency used for more severe infections.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "High doses may lead to hypernatraemia (owing to sodium content of preparations)",
                "html": "High doses may lead to hypernatraemia (owing to sodium content of preparations)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Cholestatic jaundice",
                "textContent": "Cholestatic jaundice is possibly associated with clavulanic acid. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav (amoxicillin, clavulanic acid) than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.",
                "html": "<p>Cholestatic jaundice is possibly associated with clavulanic acid. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav (amoxicillin, clavulanic acid) than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Eosinophilia",
                        "html": "Eosinophilia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "haemorrhagic cystitis (more frequent in children)",
                        "html": "haemorrhagic cystitis (more frequent in children)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypokalaemia",
                        "html": "hypokalaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful.",
                "html": "<p>Not known to be harmful.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Trace amounts in milk, but appropriate to use.",
                "html": "<p>Trace amounts in milk, but appropriate to use.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in severe impairment.",
                "html": "<p>Manufacturer advises caution in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose to 3.2 g every eight hours if eGFR 30&#8211;60 mL/minute/1.73 m2; 1.6 g every eight hours if eGFR 10&#8211;30 mL/minute/1.73 m2; 1.6 g every twelve hours if eGFR less than 10 mL/minute/1.73 m2.",
                "html": "<p>Reduce dose to 3.2&#8239;g every eight hours if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 1.6&#8239;g every eight hours if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 1.6&#8239;g every twelve hours if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Accumulation of electrolytes contained in preparation can occur in patients with renal failure.",
                "html": "<p>Accumulation of electrolytes contained in preparation can occur in patients with renal failure.</p>"
            }
        ]
    },
    "effectOnLaboratoryTests": {
        "effectOnLaboratoryTests": [
            {
                "type": "effectOnLaboratoryTests",
                "textContent": "False-positive urinary glucose (if tested for reducing substances).",
                "html": "<p>False-positive urinary glucose (if tested for reducing substances).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Timentin ), give intermittently in Glucose 5%. Suggested volume (depending on dose) 100&#8211;150 mL; give over 30&#8211;40 minutes.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Timentin</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Glucose 5%. Suggested volume (depending on dose) 100&#8211;150&#8239;mL; give over 30&#8211;40 minutes.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Dose is expressed as a combination of ticarcillin (as sodium salt) and clavulanic acid (as potassium salt) in a ratio of 15:1.",
                "html": "<p>Dose is expressed as a combination of ticarcillin (as sodium salt) and clavulanic acid (as potassium salt) in a ratio of 15:1.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76285",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78491",
                "label": "Blood infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78502",
                "label": "Penicillins",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_180",
                "label": "Ticarcillin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34546",
                "label": "PENICILLINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76285",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}